Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17234602 | 1.00 | GABRR1 (0.42) | GABRR1MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL18541279 | 1.00 | GABRR1 (0.42) | GABRR1MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL3148606 | 0.85 | MAPK1 (0.41) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL1298054 | 0.85 | MAPK1 (0.41) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL18272645 | 0.85 | CHRM2 (0.34) | GABRR1MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL295484 | 0.81 | MAPK1 (0.43) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL18346713 | 0.81 | MAPK1 (0.43) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL19134374 | 0.81 | MAPK1 (0.43) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL18828485 | 0.81 | MAPK1 (0.43) | MAPK1CHRM2CHRM1CHRM3BTK | |
| SCHEMBL12994215 | 0.80 | EPHX1 (0.39) | MAPK1CHRM2CHRM1CHRM3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | GABRR1 2359/4885MAPK1 1584/4885CHRM2 4653/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | GABRR1 2359/4885MAPK1 1584/4885CHRM2 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.